Genomic Valley Biotech Ltd (GVBL.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-77.9%

₹11.73

vs ₹53.02 price

Levered DCF

-₹9.25

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

—

Rating

C-

Overall 1 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	289.5×	47.58×	694.2×	11.09×	-783.67×	-12.85×	25.01×	30.93×
P/B	2.23×	4.35×	2.98×	2.04×	2.54×	1.6×	1.42×	1.51×
P/S	32.79×	20.1×	63.84×	2.64×	103.73×	34.52×	8.45×	7.3×
EV / EBITDA	200.37×	38.15×	630.26×	8.18×	-19.66×	-65.02×	15.29×	20.1×
Gross margin	100.0%	76.1%	100.0%	41.7%	96.5%	60.5%	98.2%	94.8%
Operating margin	60.4%	51.8%	77.3%	32.1%	-181.9%	-147.5%	45.3%	64.8%
Net margin	11.3%	42.2%	9.2%	23.8%	-13.2%	-268.7%	33.8%	23.6%
Current ratio	8.41×	5.73×	3.68×	2.89×	5.31×	0.19×	0.53×	4.14×
Debt / equity	0×	0×	0×	0×	0×	0.34×	0.29×	0.31×
Interest coverage	0×	0×	266.95×	329.25×	-518.57×	-1.71×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	0.8%	9.1%	0.4%	18.4%	-0.3%	-12.5%	5.7%	4.9%
Return on invested capital	3.1%	9.0%	3.6%	24.7%	-3.6%	-4.6%	5.3%	8.9%
Return on assets	0.7%	8.2%	0.4%	14.7%	-0.2%	-7.3%	3.6%	3.2%
Free cash flow yield	-0.2%	0.1%	-0.2%	-10.8%	-29.1%	-1.3%	-0.6%	-14.4%
Earnings yield	0.3%	2.1%	0.1%	9.0%	-0.1%	-7.8%	4.0%	3.2%
Enterprise value	₹87.7M	₹169.4M	₹105.4M	₹71.9M	₹73.2M	₹87.2M	₹85.9M	₹86M
Net debt / EBITDA	-0.1×	-0.05×	-0.14×	-0×	0×	-11.45×	2.56×	3.28×
Cash conversion cycle (days)	3,163	1,455	-603,834	157	0	-62	1,468	833